Skip to main content

Advertisement

SpringerLink
Log in

ASO Author Reflections: Neoadjuvant Therapy Versus Upfront Resection for Pancreatic Cancer

  • ASO Author Reflections
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2013;364(19):1817–25.

    Article  Google Scholar 

  2. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–703.

    Article  CAS  Google Scholar 

  3. Lim KH, Chung E, Khan A, et al. Neoadjuvant therapy of pancreatic cancer: the emerging paradigm? Oncologist. 2012;17(2):192–200.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Ferrone CR, Marchegiani G, Hong TS, et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg. 2015;261(1):12–7.

    Article  PubMed  Google Scholar 

  5. Marchegiani G, Andrianello S, Nessi C, et al. Neoadjuvant therapy versus upfront resection for pancreatic cancer: the actual spectrum and clinical burden of postoperative complications. Ann Surg Oncol. 2018; 25(3):626–37.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of General and Pancreatic Surgery, The Pancreas Institute, University of Verona Hospital Trust, Verona, Italy

    Stefano Andrianello MD, Giovanni Marchegiani MD, PhD & Roberto Salvia MD, PhD

Authors
  1. Stefano Andrianello MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giovanni Marchegiani MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Roberto Salvia MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roberto Salvia MD, PhD.

Ethics declarations

Disclosure

The authors have no conflicts of interest to disclose.

Additional information

This ASO Author Reflections is a brief invited commentary on the article “Neoadjuvant Therapy versus Upfront Resection for Pancreatic Cancer: The Actual Spectrum and Clinical Burden of Postoperative Complications,” Ann Surg Oncol. 2018; 25:626–627.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Andrianello, S., Marchegiani, G. & Salvia, R. ASO Author Reflections: Neoadjuvant Therapy Versus Upfront Resection for Pancreatic Cancer. Ann Surg Oncol 25 (Suppl 3), 810–811 (2018). https://doi.org/10.1245/s10434-018-6874-y

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-018-6874-y

Keywords

Search

Navigation